Enveric Biosciences Launches Request-For-Proposals Solicitation Process for PsyAI Trademark
Enveric Biosciences (NASDAQ: ENVB) has announced a Request-For-Proposals (RFP) process for the license or sale of its PsyAI™ trademark portfolio in the US and Canada. The company has already received two expressions of interest, initiating an auction process that will remain open until August 31, 2025.
The PsyAI™ trademark was originally intended for software applications in medical research data analytics and machine learning. However, Enveric is now focusing on developing its lead compound EB-003, a potential first-in-class neuroplastogen for depression, anxiety, and addiction disorders.
The company sees significant potential value in the PsyAI™ mark, particularly in the growing AI healthcare market. According to cited research, the global AI market is projected to reach $757B by 2025, with the mental health AI segment expected to grow from $0.9B in 2023 to $14.9B by 2033.
Enveric Biosciences (NASDAQ: ENVB) ha annunciato un processo di Richiesta di Proposte (RFP) per la licenza o la vendita del suo portafoglio di marchi PsyAI™ negli Stati Uniti e in Canada. L'azienda ha già ricevuto due manifestazioni di interesse, avviando un processo d'asta che rimarrà aperto fino al 31 agosto 2025.
Il marchio PsyAI™ era originariamente destinato a applicazioni software per l'analisi dei dati nella ricerca medica e nell'apprendimento automatico. Tuttavia, Enveric si sta ora concentrando sullo sviluppo del suo composto principale EB-003, un potenziale neuroplastogeno di prima classe per i disturbi di depressione, ansia e dipendenza.
L'azienda vede un significativo potenziale valore nel marchio PsyAI™, in particolare nel crescente mercato dell'IA nella sanità. Secondo ricerche citate, si prevede che il mercato globale dell'IA raggiunga i 757 miliardi di dollari entro il 2025, con il segmento dell'IA per la salute mentale che dovrebbe crescere da 0,9 miliardi di dollari nel 2023 a 14,9 miliardi di dollari entro il 2033.
Enveric Biosciences (NASDAQ: ENVB) ha anunciado un proceso de Solicitud de Propuestas (RFP) para la licencia o venta de su portafolio de marcas PsyAI™ en EE. UU. y Canadá. La empresa ya ha recibido dos manifestaciones de interés, iniciando un proceso de subasta que permanecerá abierto hasta el 31 de agosto de 2025.
La marca PsyAI™ estaba originalmente destinada a aplicaciones de software en análisis de datos de investigación médica y aprendizaje automático. Sin embargo, Enveric ahora se está enfocando en desarrollar su compuesto principal EB-003, un potencial neuroplastógeno de primera clase para los trastornos de depresión, ansiedad y adicción.
La empresa ve un valor potencial significativo en la marca PsyAI™, especialmente en el creciente mercado de la IA en el sector salud. Según investigaciones citadas, se proyecta que el mercado global de IA alcance los 757 mil millones de dólares para 2025, con el segmento de IA para la salud mental que se espera crezca de 0,9 mil millones de dólares en 2023 a 14,9 mil millones de dólares para 2033.
Enveric Biosciences (NASDAQ: ENVB)는 미국과 캐나다에서 PsyAI™ 상표 포트폴리오의 라이선스 또는 판매를 위한 제안 요청(RFP) 절차를 발표했습니다. 이 회사는 이미 두 건의 관심 표명을 받았으며, 경매 절차는 2025년 8월 31일까지 열려 있습니다.
PsyAI™ 상표는 원래 의료 연구 데이터 분석 및 기계 학습을 위한 소프트웨어 애플리케이션을 위해 설계되었습니다. 그러나 Enveric은 현재 우선 개발 중인 화합물 EB-003에 집중하고 있으며, 이는 우울증, 불안 및 중독 장애에 대한 잠재적인 최초의 신경 가소제입니다.
회사는 특히 성장하는 AI 헬스케어 시장에서 PsyAI™ 상표의 상당한 잠재 가치를 보고 있습니다. 인용된 연구에 따르면, 글로벌 AI 시장은 2025년까지 7570억 달러에 이를 것으로 예상되며, 정신 건강 AI 부문은 2023년 9억 달러에서 2033년까지 149억 달러로 성장할 것으로 보입니다.
Enveric Biosciences (NASDAQ: ENVB) a annoncé un processus de Demande de Propositions (RFP) pour la licence ou la vente de son portefeuille de marques PsyAI™ aux États-Unis et au Canada. L'entreprise a déjà reçu deux manifestations d'intérêt, lançant un processus d'enchères qui restera ouvert jusqu'au 31 août 2025.
La marque PsyAI™ était initialement destinée à des applications logicielles dans l'analyse des données de recherche médicale et l'apprentissage automatique. Cependant, Enveric se concentre désormais sur le développement de son composé phare EB-003, un neuroplastogène potentiel de première classe pour les troubles de la dépression, de l'anxiété et de la dépendance.
L'entreprise voit une valeur potentielle significative dans la marque PsyAI™, en particulier sur le marché croissant de l'IA dans le secteur de la santé. Selon des recherches citées, le marché mondial de l'IA devrait atteindre 757 milliards de dollars d'ici 2025, le segment de l'IA pour la santé mentale devant passer de 0,9 milliard de dollars en 2023 à 14,9 milliards de dollars d'ici 2033.
Enveric Biosciences (NASDAQ: ENVB) hat einen Anfrageprozess (RFP) für die Lizenzierung oder den Verkauf seines PsyAI™ Markenportfolios in den USA und Kanada angekündigt. Das Unternehmen hat bereits zwei Interessensbekundungen erhalten und einen Auktionsprozess eingeleitet, der bis zum 31. August 2025 geöffnet bleibt.
Die PsyAI™ Marke war ursprünglich für Softwareanwendungen in der medizinischen Forschungsdatenanalyse und im maschinellen Lernen gedacht. Enveric konzentriert sich jedoch nun auf die Entwicklung seines führenden Wirkstoffs EB-003, einem potenziellen Neuroplastogen der ersten Klasse für Depressionen, Angstzustände und Suchtstörungen.
Das Unternehmen sieht erhebliches potenzielles Wert in der PsyAI™ Marke, insbesondere im wachsenden Markt für KI im Gesundheitswesen. Laut zitierten Forschungen wird erwartet, dass der globale KI-Markt bis 2025 757 Milliarden Dollar erreichen wird, wobei der KI-Sektor für psychische Gesundheit von 0,9 Milliarden Dollar im Jahr 2023 auf 14,9 Milliarden Dollar bis 2033 wachsen soll.
- Already received two expressions of interest for PsyAI trademark
- Potential monetization opportunity through trademark sale/license
- Strategic focus on core drug development (EB-003)
- Divesting PsyAI trademark indicates shift away from AI/technology segment
- Long timeline for RFP process completion (August 2025)
The PsyAI trademark portfolio was filed with the intent to use it in “providing online non-downloadable computer software for data analytics, machine learning, knowledge management, and predictive analysis of biostatistical data and treatment data, in the field of medical research.” However, the Company has determined that it is in its best interest to focus on the development of its lead compound, EB-003, a potential first-in-class neuroplastogen designed to promote neuroplasticity without inducing hallucinations, which allows the company to pursue monetizing the PsyAI mark through the license or sale to others.
Enveric believes the PsyAI mark is well positioned for possible uses across various industries, particularly at the intersection of psychiatric medicine and Artificial Intelligence (AI). AI continues to disrupt traditional business sectors, including healthcare, that until now have been dominated by person-to-person relationships. According to Precedence Research1, the global AI market is projected to reach
The demand for AI-driven healthcare solutions is expanding, with applications in diagnostics, treatment planning, patient monitoring, and personalized medicine. AI-powered platforms, including interactive interfaces and avatars, are increasingly used for remote consultations, decision support, and predictive analytics. Many organizations are actively developing AI-driven software for research, clinical applications, and healthcare data analytics, leveraging machine learning and automation to enhance efficiency and patient outcomes. The PsyAI™ mark could serve as a valuable asset in these evolving healthcare markets, supporting AI-drive advancements across multiple medical disciplines.
The period for receiving RFPs for license or sale of the PsyAI portfolio is now open and will remain open until August 31, 2025, with a decision to follow within three (3) months thereafter. RFPs are expected to include an outline of the services for which the proposer expects to use the mark, its corporate history in AI and expected future commitment to AI-supported services, and its proposed key financial and business terms. The RFPs will be received by Enveric in confidence at cgegenheimer@enveric.com.
“We are pleased to have already received expressions of interest in license or purchase of the Enveric’s PsyAI mark and are excited about the potential receipt of RFPs as a path to private auction and maximizing the value captured from this asset. We believe that in the current technology environment this trademark portfolio holds considerable value for those seeking to penetrate the market for services that can positively impact research and support patients in the psychiatric and counseling markets,” said Joseph Tucker, Ph.D., CEO of Enveric. "Now that Enveric is fully focused on the development of EB-003, the PsyAI mark is no longer central to our core growth strategy. We believe this RFP process can be another way in which Enveric can seek to derive value from its assets while it continues its leadership role in the industry by advancing the development of our innovative drug candidate, EB-003, for the treatment of neuropsychiatric conditions.”
About Enveric Biosciences
Enveric Biosciences (NASDAQ: ENVB) is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders. Leveraging its unique discovery and development platform, the Psybrary™, which houses proprietary information on the use and development of existing and novel molecules for specific mental health indications, Enveric seeks to develop a robust intellectual property portfolio of novel drug candidates. Enveric’s lead molecule, EB-003, is a potential first-in-class neuroplastogen designed to promote neuroplasticity, without inducing hallucinations, in patients suffering from difficult-to-address mental health disorders. Enveric is focused on advancing EB-003 towards clinical trials for the treatment of neuropsychiatric disorders while out-licensing other novel, patented Psybrary™ drug candidates to third-party licensees advancing non-competitive market strategies for patient care. Enveric is headquartered in
Forward-Looking Statements
This press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as "plans," "expects" or "does not expect," "proposes," "budgets," "explores," "schedules," "seeks," "estimates," "forecasts," "intends," "anticipates" or "does not anticipate," or "believes," or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, should, would, or might occur or be achieved. Forward-looking statements may include statements regarding beliefs, plans, expectations, or intentions regarding the future and are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including, but not limited to, the ability of Enveric to: finalize and submit its IND filing to the
A discussion of these and other factors, including risks and uncertainties with respect to Enveric, is set forth in Enveric’s filings with the Securities and Exchange Commission, including Enveric’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Enveric disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
_____________________________
1 https://www.precedenceresearch.com/artificial-intelligence-market
2 https://www.marketsandmarkets.com/Market-Reports/artificial-intelligence-healthcare-market-54679303.html
3 https://market.us/report/ai-in-mental-health-market/
View source version on businesswire.com: https://www.businesswire.com/news/home/20250306405355/en/
Investor Relations
Tiberend Strategic Advisors, Inc.
David Irish
(231) 632-0002
dirish@tiberend.com
Media Relations
Tiberend Strategic Advisors, Inc.
Casey McDonald
(646) 577-8520
cmcdonald@tiberend.com
Source: Enveric Biosciences
FAQ
When does Enveric Biosciences (ENVB) close its RFP process for the PsyAI trademark?
What is the projected market value for mental health AI according to ENVB's press release?
What is ENVB's lead compound and what is it designed to do?
How many expressions of interest has ENVB received for the PsyAI trademark?
